TY - JOUR
T1 - Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation
T2 - outcomes and treatment effect across different levels of risk
AU - Joyner, Campbell D
AU - Peters, Ron J G
AU - Afzal, Rizwan
AU - Chrolavicius, Susan
AU - Mehta, Shamir R
AU - Fox, Keith A A
AU - Granger, Christopher B
AU - Franzosi, Maria Grazia
AU - Flather, Marcus
AU - Budaj, Andrzej
AU - Bassand, Jean-Pierre
AU - Yusuf, Salim
PY - 2009/3
Y1 - 2009/3
N2 - The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%. The objectives of our study were to assess the effects of fondaparinux compared to enoxaparin in patients stratified by their Global Registry of Acute Coronary Events (GRACE) score and to examine the ability of the GRACE score to predict bleeding in patients with acute coronary syndromes (ACS).
AB - The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%. The objectives of our study were to assess the effects of fondaparinux compared to enoxaparin in patients stratified by their Global Registry of Acute Coronary Events (GRACE) score and to examine the ability of the GRACE score to predict bleeding in patients with acute coronary syndromes (ACS).
UR - http://www.scopus.com/inward/record.url?scp=60649089741&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2008.10.028
DO - 10.1016/j.ahj.2008.10.028
M3 - Article
C2 - 19249421
VL - 157
SP - 502
EP - 508
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
IS - 3
ER -